🏛️ Verified NIH Record • Updated 2026-04-28

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis (NCT06260878)

🟢 Recruiting Phase4 📋 Clinical Research Protocol Sponsor: University of Calgary

🩺 Plain-English Summary (8th-Grade Level)

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (12 items).

Location: Peter Lougheed Centre — Calgary, Alberta

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

  • Intravenous Ringer's lactate (OTHER)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • prior ERCP with sphincterotomy and/or sphincteroplasty
  • confirmed or suspected cholangitis or sepsis
  • confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days
  • NYHA Class II or greater heart failure
  • active pulmonary edema
  • myocardial infarction or ischemia within the preceding 3 months
  • renal insufficiency with CrCl \< 40 mL/minute
  • CPT Class B or C cirrhosis and/or end-stage liver disease
  • room air oxygen saturation \<90% or requirement of home O2
  • uncontrolled hypertension or hypotension
  • pregnant status

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Peter Lougheed Centre — Calgary, Alberta

📞 Contact the Study Coordinator

Phone: (403) 880-8508

Email: nauzer.forbes@ucalgary.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Post-ERCP Acute Pancreatitis

Explore by condition: All Post-ERCP Acute Pancreatitis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗